Ruti Aga: Six Years of Arithmetic, and a Prescription No Clinic Ever Wrote

On Thursday the Athletics Integrity Unit released its statement and the headline carried one figure: six years. On my sheet, six is not a single number. It is two plus four — two years for presence of a substance, four for tampering with a document. The same day, most wire copy described methylprednisolone as a "prohibited steroid." On a first pass that reads as a small vocabulary error. The second pass finds the pattern: that error changes what the case actually is. I keep the raw file open while the story is being written, so here is what is not in it. The mark from that March half marathon in China appears nowhere in the source. No splits, no field depth, no conditions. I do not write the number until I can rebuild the number. What the file does support is narrower: she won the race, and an in-competition sample followed. The empty stadium made the missing data louder than the crowd — what is shouting here is the absent time. Ruti Aga is a 32-year-old Ethiopian marathoner. The 2026 Tokyo Marathon title is hers, along with three runner-up finishes at World Marathon Majors. Her personal best is not stated in the source; external recall puts 2026 Berlin at 2:18:34 and 2026 Tokyo at 2:20:40, but that is data pending verification — treat it as context, not citation. What is uncontested is that a 2:18–2:20 performer is a Major-tier athlete, and Major-tier athletes earn outside the Majors too. The March race in China belongs to that economy. It was almost certainly a World Athletics Label road race — otherwise no AIU sample would exist there. This is the tier where East African marathoners collect appearance fees, and it is now the AIU's highest-yield testing ground. The income economy and the testing economy are colliding in the same races. Now the substance. Methylprednisolone is a glucocorticoid, WADA Prohibited List class S9. Anabolic steroids sit in S1 — different class, different rules, different sanction logic. S9 is prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection out of competition is entirely legal; it becomes a violation only when residues are present in competition. On the road, the testing window opens at 23:59 the day before the race. The precise washout guidance figures are pending verification and I will not present them as numbers — but the principle is settled, and that principle was the whole defence: route, and distance from the race. The arithmetic follows. Two years for presence, four for tampering. The tampering charge did not come from a document alone; it came from an interview, meaning statements made under questioning. And the prescription was not written by a clinic. A family member posed as the doctor — no medical registration — and claimed to have used "an old prescription pad from a former workplace." The clinic did not exist, and the clinic whose name was used explicitly disowned the pad. Three independent verification failures. That is not a filing error; it is the signature of an athlete operating without a credentialed team physician. The two-year presence sanction says a great deal on its own. The knee-injury explanation is mechanistically plausible — intra-articular injection for knee synovitis is standard sports medicine in distance runners. That plausibility is exactly why the forgery is decisive. Real records would have been defended with real records. Two years also tells us the panel treated this as a Specified Substance finding without proven intent, or the sanction would have been heavier; and it tells us the no-significant-fault mitigation was rejected, or the presence period would have dropped below two years. The backdating to 10 September is not relief — it is mandatory provisional suspension time counting against the ban. In real terms the athlete gains nothing. What survives has to be tiered as well. The 2026 Tokyo title does not automatically fall; annulment is typically confined to the date of the violation absent a finding of earlier use. The source does not state the disqualification scope. Standard AIU practice is that the competition where the sample was collected is disqualified — here the March race, its result, its prize money, and ranking points accrued after that date. That is inference, and I am labelling it as inference. The career arithmetic is unforgiving. The ban expires at roughly age 38. Ethiopian women's marathon depth is such that a 2:18 performer is not automatically selectable; a 38-year-old returning with a doping record is effectively unselectable. And note who is absent from the statement: no agent, no manager, no training group. Only the family member who produced the pad. Whoever advised the fabrication, or accepted the document, is not on the ledger yet. Here is where I dissent from the comfortable reading. Six years for a glucocorticoid with no proven endurance benefit is a proportionality question worth asking out loud. But the case is not about the substance. It is about the paper. The AIU's frontier has shifted from detection to document verification, and Aga's file is the syllabus: a substance violation, then a fabricated explanation, and the fabrication tripled the sanction. The second point is a media error, not an AIU one. Write "steroid" and the reader files this alongside anabolic cases, where intent is legible and the moral verdict is easy. There is no intent here; there is negligence, panic and an uncredentialed medical network. That distinction matters for every runner who takes a knee injection without knowing how many days before a race it stays legal. Reading this as "East African road running is dirty" is the cheapest available conclusion. What the file shows is that nobody ran a TUE process for this athlete, nobody counted the washout dates, and when the questions came the answer was manufactured on paper. That is a bookkeeping failure, not a character study — though the sanction landed on the character. What to watch. First, the appeal window, typically about 21 days from the reasoned decision; the value is low, because a document-based forgery finding is hard to overturn. Second, whether an agent or manager is ever named in this family of cases. Third, whether the Ethiopian federation says anything at all — so far only the AIU is quoted. Fourth, whether testing density rises in China's label circuit, because that is where the money and the scrutiny are colliding. I will register the bet before the file closes: if not one entourage member is charged across this cluster of cases by 2026, the system is sanctioning athletes and auditing nobody. A career can be ended with a ledger. It cannot be rebuilt without one — and the prescription in this case was never on a ledger at all.